Who Supplies Empagliflozin to India from CZECH REPUBLIC

To import finished pharmaceutical formulations containing Empagliflozin into India, the following regulatory requirements must be met:

1. Import License: An Importer Exporter Code (IEC) from the Directorate General of Foreign Trade (DGFT) is mandatory. Additionally, an import license from the Central Drugs Standard Control Organization (CDSCO) is required for each consignment.

2. CDSCO Registration: The product must be registered with CDSCO. This involves submitting Form 40/41, which includes detailed information about the product, manufacturing process, and quality control measures.

3. Drug Controller General of India (DCGI) Approval: The DCGI evaluates the safety, efficacy, and quality of the product before granting approval.

4. No Objection Certificate (NOC): If the product is manufactured in a Special Economic Zone (SEZ), an NOC from the DCGI is required for transfer to the Domestic Tariff Area (DTA) for sale and distribution.

5. Timeline for Import Drug Registration: The registration process can take several months, depending on the completeness of the application and the evaluation process.

For formulations containing Empagliflozin under HS Code 30049099, compliance with the above requirements is essential to ensure legal importation and distribution in India.

Imported pharmaceutical formulations containing Empagliflozin must undergo stringent quality testing to ensure compliance with Indian standards:

1. CDSCO-Approved Laboratory Testing: Samples from each batch must be tested in laboratories approved by CDSCO to verify the product's quality, safety, and efficacy.

2. Batch-Wise Requirements: Each batch of the imported formulation must be accompanied by a Certificate of Analysis (CoA) issued by the manufacturer, detailing the product's composition, manufacturing process, and quality control measures.

3. Stability Data: Stability studies must be conducted in accordance with International Council for Harmonisation (ICH) guidelines, specifically for Zone IVa/IVb climates, to ensure the product's stability under Indian environmental conditions.

4. Indian Pharmacopoeia Standards: The formulation must comply with the standards set forth in the Indian Pharmacopoeia, which outlines the quality specifications for pharmaceutical substances and products.

5. Port Inspection: Upon arrival in India, customs drug inspectors may conduct inspections to verify the authenticity and compliance of the imported formulations with Indian regulations.

Ensuring adherence to these quality testing and certification requirements is crucial for the legal importation and distribution of Empagliflozin formulations in India.

Between 2024 and 2026, several regulatory updates have impacted the importation of finished pharmaceutical formulations into India:

1. CDSCO Regulatory Updates: The CDSCO has introduced stricter guidelines for the importation of pharmaceutical products, emphasizing enhanced quality control measures and more rigorous testing protocols.

2. Production-Linked Incentive (PLI) Scheme Impact: The PLI scheme, aimed at boosting domestic manufacturing, has led to increased scrutiny of imported formulations. While the scheme primarily targets domestic production, it has indirectly affected the import landscape by encouraging self-reliance.

3. Bilateral Agreements with Czech Republic: India and the Czech Republic have engaged in discussions to streamline trade processes, including mutual recognition of Good Manufacturing Practices (GMP) and facilitation of pharmaceutical trade.

These developments underscore the evolving regulatory environment affecting the importation of pharmaceutical formulations into India.

India imports finished Empagliflozin formulations to meet the growing demand for diabetes management therapies. The imported formulations often include patented or branded versions, specific dosage forms, or combinations not available domestically. Despite a robust domestic pharmaceutical industry, certain specialized formulations are not produced locally, necessitating imports. The market size for Empagliflozin formulations in India is substantial, with a significant portion of the demand met through imports.

The import duty structure for finished pharmaceutical formulations under HS Code 30049099 in India is as follows:

1. Basic Customs Duty (BCD): 10%

2. Education Cess: 2%

3. Secondary Higher Education Cess: 1%

4. Countervailing Duty (CVD): 6%

5. Integrated Goods and Services Tax (IGST): 12%

Additionally, a Social Welfare Surcharge (SWS) of 10% is applicable. Exemptions or concessional rates may apply under specific circumstances, such as trade agreements or special economic zones. The total landed duty percentage varies based on the product's value and applicable exemptions.

India sources finished Empagliflozin formulations from the Czech Republic due to several competitive advantages:

1. Patented Formulations: The Czech Republic offers patented Empagliflozin formulations that are not available from other suppliers.

2. Specialized Dosage Forms: Unique dosage forms or combinations developed by Czech manufacturers cater to specific patient needs, filling gaps in the Indian market.

3. Quality Assurance: Czech pharmaceutical products are known for high-quality standards and compliance with international regulations, ensuring safety and efficacy.

While other suppliers like China, Germany, and the US also export Empagliflozin formulations to India, the Czech Republic's offerings are distinguished by these factors, contributing to its share in the Indian market.